Eikon Therapeutics, Inc.

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list

Venture capital mega-rounds of $100m or more drove the overall increase in VC funding raised by biopharmaceutical companies in 2024, as Evaluate data recently revealed , and as the National Venture C

Eikon Therapeutics has raised another venture capital mega-round – bringing its total funding to date to $1.1bn – to build what it calls a “21st century biotechnology company.” The new financing will

Amid a persistent funding crunch in November, Chinese biotechs managed to edge close to bigger fund-raising deals backed by venture capital and private equity firms. Apart from a $100m-plus series A+